Loading
LCK (Tyrosine-protein kinase Lck) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target and a fusion partner, and an approved or late-stage drug is recorded against it. Tied to Leukaemia, Renal cell carcinoma, Myeloproliferative neoplasms and 5 more.
Non-receptor tyrosine-protein kinase that plays an essential role in the selection and maturation of developing T-cells in the thymus and in the function of mature T-cells. Plays a key role in T-cell antigen receptor (TCR)-linked signal transduction pathways. Constitutively associated with the cytoplasmic portions of the CD4 and CD8 surface receptors.
Open Targets scores its association with cancer at 0.81 (direct and indirect evidence; datatypes clinical 0.98, affected pathway 0.92, literature 0.95, genetic association 0.00, somatic mutation 0.97).
In plain words · LCK (Tyrosine-protein kinase Lck) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target and a fusion partner, and an approved or late-stage drug is recorded against it. Tied to Leukaemia, Renal cell carcinoma, Myeloproliferative neoplasms and 5 more.
LCK (Tyrosine-protein kinase Lck) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target and a fusion partner, and an approved or late-stage drug is recorded against it. Tied to Leukaemia, Renal cell carcinoma, Myeloproliferative neoplasms and 5 more.
Non-receptor tyrosine-protein kinase that plays an essential role in the selection and maturation of developing T-cells in the thymus and in the function of mature T-cells.
No product in this corpus aims at LCK yet. Kinases are switched on by binding ATP inside the cell, so most drugs are small molecules shaped to plug that ATP pocket.
Tumour-specific alteration: the catalogues call it a fusion partner (UniProt records a translocation); what a medicine would aim at or exploit is the altered form or its loss, absent from normal cells; no corpus medicine is aimed at it yet. HPA LCK: RNA tissue enriched (lymphoid tissue 326 nTPM); blood lineage group enriched (NK-cells 628 nTPM, T-cells 1,617 nTPM); high antibody staining in 5 normal tissues; highest cancer staining lymphoma (8 of 12 high). Distribution: 7 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Leukaemia, Renal cell carcinoma, Myeloid neoplasms, Lymphoma, Sarcomas (soft tissue, bone, GIST), Skin cancer (all types), Ovarian cancer); Open Targets associates it with 4 specific cancer types at or above 0.5 (acute lymphoblastic leukemia, chronic myeloid leukemia, renal cell carcinoma, soft tissue sarcoma). (Rule 6 of scripts/fetch-target-specificity.ts.)
Sources: UniProt P06239; Human Protein Atlas LCK tissue; Open Targets ENSG00000182866 associations
First described 1986. Earliest sequence paper UniProt cites for the protein: Koga et al, Eur. J. Immunol, 1986, "A human T cell-specific cDNA clone (YT16) encodes a protein with extensive homology to a family of protein-tyrosine kinases". Source.
Sources: HGNC HGNC:6524 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P06239 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000182866 (association with cancer (MONDO_0004992) 0.81; per-cancer scores at or above 0.5: renal cell carcinoma 0.67, ovarian cancer 0.55, melanoma 0.53, sarcoma 0.62, acute lymphoblastic leukaemia 0.64, non-Hodgkin lymphoma 0.64 (GraphQL API, CC0))
Non-receptor tyrosine-protein kinase that plays an essential role in the selection and maturation of developing T-cells in the thymus and in the function of mature T-cells. Plays a key role in T-cell antigen receptor (TCR)-linked signal transduction pathways. Constitutively associated with the cytoplasmic portions of the CD4 and CD8 surface receptors. Association of the TCR with a peptide antigen-bound MHC complex facilitates the interaction of CD4 and CD8 with MHC class II and class I molecules, respectively, thereby recruiting the associated LCK protein to the vicinity of the TCR-CD3 complex. LCK then phosphorylates tyrosine residues within the immunoreceptor tyrosine-based activation motifs (ITAM) of the cytoplasmic tails of the TCR-gamma chains and CD3 subunits, initiating the TCR-CD3 signalling pathway. Once stimulated, the TCR recruits the tyrosine kinase ZAP70, that becomes phosphorylated and activated by LCK. Location: Cell membrane; Cytoplasm, cytosol (UniProt). Locus 1p35.2 (HGNC).
RNA: tissue enriched (lymphoid tissue 326 nTPM), detected in many normal tissues. Blood: group enriched (NK-cells 628 nTPM, T-cells 1,617 nTPM).
Medium only: colorectal cancer, pancreatic cancer.
HPA LCK tissue · HPA LCK pathology · HPA protein class: FDA approved drug targets
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"LCK" OR ABSTRACT:"LCK" OR TITLE:"LCK proto-oncogene, Src family tyrosine kinase" OR ABSTRACT:"LCK proto-oncogene, Src family tyrosine kinase" OR TITLE:"Tyrosine-protein kinase Lck" OR ABSTRACT:"Tyrosine-protein kinase Lck") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about LCK, not a curated reading list.
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Acute lymphoblastic leukaemia, Non-Hodgkin lymphoma (all types).
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Acute lymphoblastic leukaemia, Ovarian cancer.
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Acute lymphoblastic leukaemia, Ovarian cancer.
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Acute lymphoblastic leukaemia, Ovarian cancer.
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Acute lymphoblastic leukaemia, Ovarian cancer.
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Acute lymphoblastic leukaemia, Ovarian cancer.
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Acute lymphoblastic leukaemia, Ovarian cancer.
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Acute lymphoblastic leukaemia, Ovarian cancer.